Sarepta Therapeutics (SRPT) Total Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 27.93% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (down 27.93% YoY), while the FY2025 annual figure was $2.2 billion, down 9.29% from the prior year.
• Total Liabilities was $1.7 billion for Q1 2026 at Sarepta Therapeutics, down from $2.2 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.7 billion in Q4 2022 to a low of $1.7 billion in Q1 2026.
• Historically, Total Liabilities has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities grew 24.29% in 2022, then fell 27.93% in 2026.
• A 5-year view of Total Liabilities shows it stood at $2.7 billion in 2022, then dropped by 12.33% to $2.4 billion in 2023, then advanced by 1.26% to $2.4 billion in 2024, then retreated by 9.29% to $2.2 billion in 2025, then declined by 24.23% to $1.7 billion in 2026.
• The last three Total Liabilities figures came in at $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.